The University of California, Irvine
Orange, United States
Through this I express my interest in running for office at the World Muscle Society. Being a long-term member of the Society and having attending multiple meetings, I strongly believe in the vision of the society and will do my best to further it and enhance it. Muscle disorders play a big role in my life with my clinical practice almost exclusively devote to clinical care and muscle pathology interpretation. I have played leadership role at my institution and nationally in Neurology and Neuromuscular Disorders (Division Director of the Neuromuscular Disease, Chair of the Department, Section Head of the Neuromuscular Section at the American Academy of Neurology, and currently member of the Scientific Advisory Board and Of the Board of Directors for the Myositis Association). I have a strong track record of promoting equity and diversity and have mentored many individuals both locally, nationally and internationally.
Respectfully,
Tahseen Mozaffar, MD
Dr. Tahseen Mozaffar is a Professor of Neurology and Pathology and Laboratory Medicine and the Vice Chair for Research in the Department of Neurology at University of California, Irvine. He is the Director of the UC Irvine-MDA ALS and Neuromuscular Center and the Director of the UC Irvine Neuromuscular Program. Dr. Mozaffar serves as chair of one of the biomedical committees and the institutional liaison for Trials Innovation Hub for the Center for Translational Sciences Award (CTSA) at University of California, Irvine. He is the Principal Investigator for UCI-NEXT, the NeuroNEXT award to the University of California, Irvine, one of 25 such NeuroNEXT sites funded by the NINDS/NIH. He is also the Lead Investigator for a multicenter NIH/NIAMS funded Natural History Study in sIBM (INSPIRE-IBM), scheduled to start July 2021.
At UCI he has built an internationally recognized clinical and research program in Neuromuscular Disorders. He is actively involved in clinical and translational research in Neuromuscular Disorders, including currently serving as Principal Site Investigator on over a dozen clinical trials in myasthenia gravis, rare and ultra-rare myopathies and in immune myopathies. He has co-authored over 175 peer-reviewed publications and has authored or co-authored over a dozen book chapters and invited reviews. As an expert in these rare and ultra-rare myopathies, he is actively sought as an advisor by pharmaceutical companies for trial design and identifying disease targets. He serves on a global advisory board for Pompe at Amicus and for Spark Therapeutics. He has served on the Data Safety Monitoring Board for Acceleron, Sarepta and NIH. He is a standing study section member for the ETTN study section at the NIH. He is a member of the Medical Advisory Board for the Myositis Association and serves as the MAB Liaison to the Board at TMA. He serves on the Board of Directors at the Neuromuscular Disease Foundation.
